3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Lymphoid
2
Breast
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
1
Melanoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
100
Nivolumab
69
Cyclophosphamide
67
Ipilimumab
66
fludarabine
34
aldesleukin
29
fludarabine phosphate
28
Vemurafenib
28
Interleukin-2
26
trametinib
20
Biopsy
20
dabrafenib
17
Radiotherapy
16
Temozolomide
15
Cisplatin
15
Magnetic Resonance Spectroscopy
14
Gemcitabine
14
Filgrastim
14
atezolizumab
13
Specimen Handling
13
Carboplatin
13
CTLA-4 Antigen
13
spartalizumab
12
romidepsin
12
Paclitaxel
12
Bortezomib
11
poly ICLC
10
cobimetinib
10
Peripheral Blood Stem Cell Transplantation
10
Oxaliplatin
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
merestinib
×
Dermatologic
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled